A rabbit monoclonal antibody against mouse CD36 and its application

By developing rabbit monoclonal antibodies with specific amino acid sequences and expressing them in host cells, the problem of the lack of mouse CD36 detection antibodies in flow cytometry has been solved, achieving efficient and accurate detection of CD36-positive cells.

CN123106907APending Publication Date: 2026-11-17WUHAN AIBO TAIKE BIOTECH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611534905.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-30
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies lack rabbit monoclonal antibodies suitable for flow cytometry detection of mouse CD36, and mouse monoclonal antibodies suffer from problems such as low B cell count, low diversity of immune responses, high tolerability, large molecular weight, and poor consistency.

Method used

A rabbit monoclonal antibody against mouse CD36 was developed, containing specific amino acid sequences of complementary regions of the light and heavy chain variable regions. The antibody was expressed in host cells via a recombinant vector to prepare a rabbit monoclonal antibody conjugate suitable for flow cytometry, which is used to specifically bind to CD36 on the surface of mouse cells.

Benefits of technology

This method enables specific detection of mouse CD36-positive cells, enriches the flow cytometry antibody library, improves the accuracy and consistency of detection, and overcomes the shortcomings of mouse-derived antibodies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106907A_ABST
    Figure CN123106907A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biotechnology and relates to a rabbit monoclonal antibody against mouse CD36 and its applications. The rabbit monoclonal antibody comprises complementarity-determining regions (CDD1, LCDR2, and LCDR3) of the light chain variable region and CDD1, CDD2, and CDD3 of the heavy chain variable region; wherein the amino acid sequences of LCDR1-3 are as shown in SEQ ID NO:3-5, and the amino acid sequences of CDD1-3 are as shown in SEQ ID NO:8-10. The rabbit monoclonal antibody provided by this invention can specifically bind to CD36 on the surface of mouse cells and is suitable for the detection of CD36-positive cells in flow cytometry.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biotechnology and relates to a rabbit monoclonal antibody against mouse CD36 and its application. Background Technology

[0002] CD36 is a B-group scavenger receptor widely expressed on the surface of various cells, including macrophages, platelets, and microvascular endothelial cells, and participates in key physiological processes such as fatty acid metabolism, immune regulation, angiogenesis, and inflammatory responses. Studies have shown that CD36 plays a dual role in the development of various major diseases: In the field of oncology, CD36 promotes tumor growth, immune escape, metastasis, and drug resistance by mediating lipid metabolism; monoclonal antibodies targeting CD36 can reverse the immunosuppressive state of the tumor microenvironment and enhance anti-tumor immune responses through metabolic reprogramming. In cardiovascular diseases, CD36 mediates the uptake of oxidized low-density lipoprotein (oxLDL) by macrophages, promoting foam cell formation and the progression of atherosclerosis. In addition, CD36 antibodies can also mediate immune diseases such as transfusion-associated acute lung injury (TRALI) and fetal / neonatal alloimmune thrombocytopenic purpura (FNAIT).

[0003] Given the crucial pathological role of CD36 in tumors, cardiovascular diseases, and immune diseases, the development of monoclonal antibodies targeting CD36 holds promise for providing novel therapeutic strategies to address these clinical challenges by blocking its pathogenic function. However, most commercially available CD36 antibodies are monoclonal antibodies derived from rats, hamsters, or mice, which have the following limitations:

[0004] 1) The development of mouse monoclonal antibody systems is limited by the small body size and small spleen of mice, resulting in a small number of B cells that can be obtained;

[0005] 2) Most mouse strains currently in use are inbred strains, which lead to a significant reduction in the diversity of immune responses;

[0006] 3) Long-term use of mouse monoclonal antibodies may lead to the immune system developing tolerance to mouse antigens, thereby reducing their efficacy;

[0007] 4) The complex subtype classification of mouse monoclonal antibodies increases the difficulty of antibody preparation;

[0008] 5) The large molecular weight of mouse monoclonal antibodies limits their application scenarios;

[0009] 6) There may be some differences between different batches of mouse monoclonal antibodies, which may affect their consistency and stability.

[0010] In contrast, rabbit monoclonal antibodies offer advantages such as high B cell library diversity, stable IgG structure without complex subclasses, strong immune response, and easier acquisition of high-affinity antibodies. However, rabbit monoclonal antibodies suitable for flow cytometry detection of mouse CD36 are currently relatively scarce. Summary of the Invention

[0011] To address the lack of commercially available rabbit monoclonal antibodies for the detection of mouse CD36 by flow cytometry, this invention provides a rabbit monoclonal antibody against mouse CD36 and its application.

[0012] The technical solution provided by this invention is as follows:

[0013] In a first aspect, the present invention provides a rabbit monoclonal antibody against mouse CD36, comprising complementarity-determining regions LCDR1, LCDR2, and LCDR3 of the light chain variable region, and complementarity-determining regions HCDR1, HCDR2, and HCDR3 of the heavy chain variable region; wherein:

[0014] The amino acid sequence of LCDR1 is shown in SEQ ID NO:3, the amino acid sequence of LCDR2 is shown in SEQ ID NO:4, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:5.

[0015] The amino acid sequence of HCDR1 is shown in SEQ ID NO:8, the amino acid sequence of HCDR2 is shown in SEQ ID NO:9, and the amino acid sequence of HCDR3 is shown in SEQ ID NO:10.

[0016] In conjunction with the first aspect of the present invention, in some embodiments: the rabbit monoclonal antibody comprises a light chain variable region with an amino acid sequence as shown in SEQ ID NO:2, and a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:7.

[0017] In conjunction with the first aspect of the present invention, in some embodiments: the rabbit monoclonal antibody is rabbit IgG, which has a light chain with an amino acid sequence as shown in SEQ ID NO:1 and a heavy chain with an amino acid sequence as shown in SEQ ID NO:6.

[0018] In conjunction with the first aspect of the present invention, in some embodiments: the rabbit monoclonal antibody is a full-length antibody or its antigen-binding fragment; the antigen-binding fragment is selected from at least one of the Fab fragment, F(ab')2 fragment, Fv fragment, scFv fragment and (scFv)2 fragment.

[0019] In a second aspect, the present invention provides a nucleic acid molecule comprising a nucleotide sequence encoding the rabbit monoclonal antibody described in the first aspect.

[0020] In conjunction with the second aspect of the present invention, in some embodiments: the nucleotide sequence encoding the light chain variable region of the rabbit monoclonal antibody is shown in SEQ ID NO:12, and the nucleotide sequence encoding the heavy chain variable region of the rabbit monoclonal antibody is shown in SEQ ID NO:14.

[0021] In conjunction with the second aspect of the present invention, in some embodiments: the nucleotide sequence encoding the full length of the light chain of the rabbit monoclonal antibody is shown in SEQ ID NO:11, and the nucleotide sequence encoding the full length of the heavy chain of the rabbit monoclonal antibody is shown in SEQ ID NO:13.

[0022] Thirdly, the present invention provides a recombinant vector carrying the aforementioned nucleic acid molecules.

[0023] Fourthly, the present invention provides a host cell comprising the above-mentioned nucleic acid molecules or the above-mentioned recombinant vector.

[0024] Fifthly, the present invention provides an antibody conjugate comprising the rabbit monoclonal antibody described in the first aspect, and a detection marker linked to the rabbit monoclonal antibody.

[0025] Sixthly, the present invention provides a kit for detecting mouse CD36, the kit comprising:

[0026] (1) Detect an effective amount of the above-mentioned rabbit monoclonal antibody;

[0027] (2) The reagents for detection are selected from one or more of the following: buffer solution, labeled secondary antibody, blocking agent, washing solution and chromogenic substrate.

[0028] In conjunction with the sixth aspect of the present invention, in some embodiments: the kit is a kit for flow cytometry detection of cells expressing mouse CD36.

[0029] In a seventh aspect, the present invention provides the application of the above-mentioned rabbit monoclonal antibody in the preparation of a product for detecting mouse CD36, wherein the detection is performed by flow cytometry.

[0030] In conjunction with the seventh aspect of the present invention, in some embodiments, the product is a test kit or test reagent.

[0031] Compared with the prior art, the present invention has at least the following beneficial effects:

[0032] The rabbit monoclonal antibody against mouse CD36 provided by this invention can specifically bind to CD36 on the surface of mouse cells, and is suitable for the detection of mouse CD36 positive cells, especially the detection of mouse CD36 positive cells in flow cytometry, thus enriching the flow cytometry antibody library. Attached Figure Description

[0033] To more clearly illustrate the technical solutions in the embodiments of the present invention, the accompanying drawings used in the description of the embodiments will be briefly introduced below. Obviously, the accompanying drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0034] Figure 1 : Schematic diagram of the recombinant vector used to express the heavy chain constant region gene of the candidate antibody in Example 1.

[0035] Figure 2 : Schematic diagram of the expression vector used to express the light chain constant region gene of the candidate antibody in Example 1.

[0036] Figure 3 Flow cytometry analysis results of rabbit monoclonal antibody group A and isotype control group in Example 2 (positive sample is C57BL / 6 mouse bone marrow induced macrophage M0); where: A: scatter plot of isotype control group, B: scatter plot of rabbit monoclonal antibody group A.

[0037] Figure 4 The flow cytometry analysis results of the commercially available control group in Example 2 (positive sample was C57BL / 6 mouse bone marrow induced macrophage M0), and the commercially available control product was APC anti-mouse CD36 Antibody. Detailed Implementation

[0038] To make the objectives, technical solutions, and advantages of this invention clearer, the technical solutions of this invention will be clearly and completely described below in conjunction with the embodiments of this invention. Obviously, the described embodiments are only some, not all, of the embodiments of this invention. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this invention.

[0039] In the embodiments of the present invention, unless otherwise specified, all raw material components are commercially available products well known to those skilled in the art; unless specifically specified, the technical means used are all conventional means well known to those skilled in the art.

[0040] This invention provides a rabbit monoclonal antibody against mouse CD36, comprising light chain variable region complementarity-determining regions LCDR1, LCDR2, and LCDR3, and heavy chain variable region complementarity-determining regions HCDR1, HCDR2, and HCDR3; wherein: the amino acid sequence of LCDR1 is shown in SEQ ID NO:3, the amino acid sequence of LCDR2 is shown in SEQ ID NO:4, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:5; the amino acid sequence of HCDR1 is shown in SEQ ID NO:8, the amino acid sequence of HCDR2 is shown in SEQ ID NO:9, and the amino acid sequence of HCDR3 is shown in SEQ ID NO:10.

[0041] The complementarity-determining region (CDR) is a key region for antibody recognition of antigens, determining the antibody's specificity and affinity. In this invention, the amino acid sequences of LCDR1-3 and HCDR1-3 are shown in SEQ ID NO: 3-5 and 8-10, respectively, and are taken as the standard. Those skilled in the art can use well-known numbering systems such as IMGT, Kabat, Chothia, or AbM to classify the CDRs. Different numbering systems may define the boundaries of the CDRs differently, but this does not affect the determination of the CDR sequences described in this invention. Specifically, in the embodiments of this invention, the CDRs are classified according to the IMGT numbering system. The rabbit monoclonal antibody provided by this invention can specifically bind to CD36 in its native conformation on the surface of mouse cells, meeting the application requirements of flow cytometry detection.

[0042] The frame region (FR, the non-CDR portion of the variable region) stabilizes the spatial conformation of the CDR, determines whether the CDR can fold correctly into an effective binding pocket, and affects the antibody's thermal stability, pH stability, and expression efficiency. In this invention, the amino acid sequence of the light chain variable region of the rabbit monoclonal antibody is shown in SEQ ID NO:2, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:7.

[0043] The constant region provides effector function. Rabbit IgG has a stable structure and a relatively simple composition, exhibiting higher stability and lower development difficulty compared to the various isotypes of mouse monoclonal antibodies. In some embodiments of the present invention, the rabbit monoclonal antibody is rabbit IgG, whose full-length light chain amino acid sequence is shown in SEQ ID NO:1, and its full-length heavy chain amino acid sequence is shown in SEQ ID NO:6.

[0044] In some embodiments of the present invention, the rabbit monoclonal antibody is a full-length antibody (IgG). To improve the diffusion rate, a smaller, faster-diffusion fragment antibody, i.e., an antigen-binding fragment, can be selected to replace the full-length antibody. Preferably, the antigen-binding fragment is selected from at least one of the following: Fab fragment, F(ab')2 fragment, Fv fragment, scFv fragment, and (scFv)2 fragment.

[0045] The antigen-binding fragments described above all contain the same CDR sequence as the full-length antibody, thus retaining their ability to specifically bind to CD36, the native conformation of mouse cells. These antigen-binding fragments can be obtained using conventional methods in the art, such as by enzymatic digestion of the full-length antibody with a protease, or by recombinant expression of the corresponding fragment.

[0046] To address the problems of low yield, loss of antibody genes during long-term passage, and difficulty in large-scale production of antibodies using traditional hybridoma cells, this invention provides a nucleic acid molecule, a recombinant vector carrying the nucleic acid molecule, and a host cell containing the nucleic acid molecule or the recombinant vector. The nucleic acid molecule carries the genetic information of the rabbit monoclonal antibody, and the recombinant vector serves as a delivery vehicle for introducing the nucleic acid molecule into the host cell. After culture, the host cell can express and secrete the rabbit monoclonal antibody, thereby achieving large-scale, batch-stable recombinant preparation of the antibody. In some embodiments of this invention, the host cell is a 293F cell.

[0047] In some embodiments of the present invention, the nucleotide sequence encoding the light chain variable region is shown in SEQ ID NO:12, which corresponds to the amino acid sequence encoding the light chain variable region of the rabbit monoclonal antibody (SEQ ID NO:2); the nucleotide sequence encoding the heavy chain variable region is shown in SEQ ID NO:14, which corresponds to the amino acid sequence encoding the heavy chain variable region of the rabbit monoclonal antibody (SEQ ID NO:7).

[0048] In some embodiments of the present invention, the nucleotide sequence encoding the full length of the light chain is shown in SEQ ID NO:11, which corresponds to the amino acid sequence encoding the full length of the light chain of the rabbit monoclonal antibody (SEQ ID NO:1); the nucleotide sequence encoding the full length of the heavy chain is shown in SEQ ID NO:13, which corresponds to the amino acid sequence encoding the full length of the heavy chain of the rabbit monoclonal antibody (SEQ ID NO:6).

[0049] The present invention also provides an antibody-drug conjugate comprising the aforementioned rabbit monoclonal antibody and a detection marker linked to the rabbit monoclonal antibody. In the rabbit monoclonal antibody-drug conjugate, the antibody portion is used to specifically bind to mouse CD36, and the linked detection marker is used to generate a detectable signal, thereby enabling the detection of mouse CD36. In some embodiments of the present invention, the detection marker is one of a fluorescent marker, an enzyme marker, a biotinylate, or a radiolabel.

[0050] The present invention also provides the application of the above-mentioned rabbit monoclonal antibody in the preparation of a product for detecting mouse CD36, wherein the detection is performed by flow cytometry.

[0051] Preferably, the product for detecting mouse CD36 is a flow cytometry kit for detecting mouse CD36.

[0052] As shown in Example 2 (flow cytometry), the rabbit monoclonal antibody can specifically bind to mouse CD36 in an intact cell system; this detection effect depends on the rabbit monoclonal antibody's ability to recognize mouse CD36 in its native conformation.

[0053] The present invention also provides a kit for detecting mouse CD36, the kit comprising: (1) a detection-effective amount of rabbit monoclonal antibody; and (2) a detection reagent selected from one or more of buffer, labeled secondary antibody, blocking agent, washing solution, and chromogenic substrate. The detection-effective amount refers to the antibody concentration or amount required to generate a detectable specific signal when using the rabbit monoclonal antibody provided by the present invention, and can be determined according to the detection method, sample type, and detection system.

[0054] In some embodiments of the present invention, the kit is a kit for flow cytometry detection of cells expressing mouse CD36.

[0055] The present invention also provides a method for preparing the above-mentioned rabbit monoclonal antibody, comprising the following steps: loading the heavy chain gene and light chain gene encoding the rabbit monoclonal antibody into expression vectors respectively, transfecting 293F cells, culturing to obtain a supernatant containing the rabbit monoclonal antibody, purifying to obtain the above-mentioned rabbit monoclonal antibody.

[0056] The technical solution of the present invention will be described in detail below through specific embodiments. In the following embodiments:

[0057] C57BL / 6 mouse bone marrow-induced macrophages M0 were prepared by in vitro induction and differentiation of C57BL / 6 mouse bone marrow cells and were used as positive samples for flow cytometry detection.

[0058] The antigen used for ELISA coating was recombinant mouse CD36 protein, and its preparation method is described in Section 1.1 of Example 1.

[0059] The enzyme-labeled secondary antibody used in the ELISA assay was horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG.

[0060] Example 1: Preparation of rabbit monoclonal antibody against mouse CD36

[0061] The preparation steps of the rabbit monoclonal antibody against mouse CD36 in this embodiment are as follows:

[0062] 1.1 Preparing the immunogen:

[0063] The immunogen used in this embodiment is recombinant mouse CD36 protein, which is prepared as follows:

[0064] Using the nucleotide sequence corresponding to the mouse CD36 protein sequence (NCBI accession number: NP_031669.3; UniProt ID: Q08857) (NCBI accession number: NM_007643.5), the XY02A (IL2ss+C-6×His) vector was constructed. The endotoxin-free recombinant expression vector plasmid was then transfected into HEK293F cells. The specific process is as follows: (1) Before transfection, HEK293F cells were passaged until the cell density reached approximately 3×10⁻⁶ cells / year. 6 ~4×10 6 (1) Live cells / mL, and cell viability ≥95%; (2) One day before transfection (day -1), the cells from step (1) were divided into 1.5×10⁻⁶ cells / mL. 6 ~1.8×10 6 (2) Seed cells at a density of 10 cells / mL and allowed to grow overnight; (3) On the day of transfection (day 0), obtain data including cell density and viability. Before transfection, adjust the density of HEK293F cells to 3.0 × 10⁻⁶ cells / mL. 6Cells / mL, cell volume of 500 mL, cell viability ≥95% after transfection; (4) Add 500 μg recombinant plasmid DNA to 25 mL Opti-MEM medium, and add 1.25 mL PEI MAX solution (pH 7.1, purchased from Polysciences, trade name PEI MAX - Transfection Grade Linear Polyethylenimine Hydrochloride (MW 40000), catalog number 24765-1) to 25 mL Opti-MEM medium (purchased from: Opti-MEM, catalog number: 81075-001), then mix the DNA solution and PEI solution to obtain a DNA / PEI mixed solution; (5) add the DNA / PEI mixed solution from step (4) to the HEK293 cell solution from step (3), mix thoroughly, incubate at room temperature for about 20 min, and perform plasmid transfection; (6) place the transfected HEK293F cells in a constant temperature shaker at 37℃, 8% CO2, and 95% humidity, and the shaker speed is 125 rpm; (7) add 5% (v / v) 293-ProFeed (purchased from: Opti-MEM, catalog number: F081918-001) and glucose (glucose) with a final concentration of 4 g / L to the cell culture medium 16-22 h after transfection to induce transient expression of the target gene on the recombinant expression vector, and harvest the cells when the cell viability is less than 70%. High-quality, bioactive recombinant mouse CD36 mature protein was obtained by purification using His-tag affinity chromatography.

[0065] 1.2 Animal Immunization:

[0066] Four New Zealand white rabbits were immunized using recombinant mouse CD36 protein as an immunogen. Each rabbit received a dose of 200 μg. Before the first immunization, the immunogen was mixed with an equal volume of complete Freund's adjuvant (purchased from Sigma) to form an emulsion, which was then injected subcutaneously at multiple sites on the rabbit's abdomen and back. Every three weeks after the first immunization, 100 μg of the immunogen was mixed with an equal volume of incomplete Freund's adjuvant (purchased from Sigma) to form an emulsion, which was then injected subcutaneously at multiple sites on the rabbit's abdomen and back for two booster immunizations. Serum from the immunized rabbits was collected after the three immunizations, and the serum titer against mouse CD36 was determined using ELISA (see Section 1.2.1 for details). Based on the titer results, 200 μg of the immunogen was injected subcutaneously at multiple sites to complete the final booster immunization. The spleen was harvested three days after the final booster immunization, and the serum titer results are shown in Table 1.

[0067] 1.2.1 ELISA titer detection:

[0068] This experiment used an indirect ELISA method to detect the titer of anti-mouse CD36 specific antibodies in immunized rabbit serum. The specific steps are as follows:

[0069] 1.2.1.1 Coating:

[0070] Recombinant mouse CD36 protein was diluted with 1×PBS buffer to a final concentration of 1 μg / mL to obtain antigen coating solution. The antigen coating solution was added to 384-well plates, with a sample volume of 25 μL per well. After balancing the 384-well plates, they were briefly centrifuged (stopping centrifugation after reaching 1000 rpm) and then incubated overnight at 4°C to obtain coated plates.

[0071] 1.2.1.2 Closure:

[0072] Add 75 μL of washing buffer (PBS containing 0.05% (v / v) Tween-20) to each well of the coated plate using a plate washer, and repeat the washing process 5 times. Add 50 μL of blocking buffer (PBS containing 1% BSA, 0.5% gelatin, and 5% sucrose) to each well using a multichannel pipette, and incubate at room temperature for 1 h to block non-specific binding sites. If a large number of samples need to be tested and batch processing is required, an S-Pipette pipetting workstation can be used for batch sample addition.

[0073] 1.2.1.3 Sample gradient dilution and loading:

[0074] Repeat the washing procedure described in Section 1.2.1.2 for the well plate. Take a 96-well plate and, using dilution buffer (PBS containing 1% (v / v) BSA) as the diluent, perform a three-fold serial dilution of the serum sample to be tested, starting at a 1:1000 ratio, for a total of 8 dilution ratios. Among them:

[0075] Immunized rabbit serum was added as the primary antibody to the immunized rabbit serum group;

[0076] The negative control group was supplemented with serum from unimmunized normal rabbits as the primary antibody;

[0077] The blank control group was treated with dilution buffer instead of immunized rabbit serum as the primary antibody.

[0078] The diluted samples were then transferred to the 384-well plate coated in section 1.2.1.1, with 25 μL added to each well.

[0079] 1.2.1.4 Secondary antibody incubation:

[0080] Repeat the plate washing procedure described in section 1.2.1.2. Dilute goat anti-rabbit IgG-HRP 1:5000 with dilution buffer, and add 25 μL of the diluted goat anti-rabbit IgG-HRP to each well using a multichannel pipette. Incubate at room temperature in the dark for 1 h.

[0081] 1.2.1.5 ELISA colorimetric and titer determination:

[0082] After washing five times with washing buffer and patting dry, add 100 μL TMB substrate solution to each well and incubate at room temperature in the dark for 15 min. Stop the reaction by adding stop solution when the positive wells turn a distinct blue. Read the OD value at 450 nm using a microplate reader. ELISA titer analysis showed that the immune rabbit serum had a high titer of positive results against mouse CD36, indicating that the recombinant mouse CD36 protein has good immunogenicity and can induce rabbits to produce high-titer anti-mouse CD36 specific antibodies. Based on this, the OD value at a 1:243K dilution was selected. 450 Rabbits with a titer greater than 0.2 received a final booster immunization.

[0083] Table 1 ELISA titer detection results (OD) 450 )

[0084]

[0085] Where K represents ×10 3 For example, 1:243K means the serum was diluted at a ratio of 1:243000; immune rabbit serum groups 1-4 represent 4 rabbits.

[0086] As shown in Table 1, the OD450 values ​​of the fourth-immune serum from groups 1, 3, and 4 of the immunized rabbit serum exceeded 0.2 (0.209~0.218, 0.345~0.367, 0.214~0.216) at a dilution ratio of 1:243K, which were all higher than those of the third-immune serum. The OD450 values ​​of the immunized rabbit serum from each group at each dilution ratio were significantly higher than those of the negative control group (0.025~0.031) and the blank control group (0.015~0.016), indicating that the recombinant mouse CD36 protein has good immunogenicity and can induce rabbits to produce specific antibodies.

[0087] 1.3 Spleen cell isolation:

[0088] Three days after the final booster immunization, rabbits were euthanized, and their spleens were harvested. Under aseptic conditions in a biosafety cabinet, 30-40 mL of basal culture medium was added to a sterile culture dish. A cell strainer was placed on top, and the spleen was then positioned on the strainer. Excess connective tissue and fat on the surface of the spleen tissue were first removed. The spleen tissue was then minced and transferred to the cell strainer for grinding. The tissue was continuously ground using the end of a sterile grinding rod to fully release the spleen cells. The released cells were then suspended in the basal culture medium in the culture dish through the cell strainer. The cell strainer was then rinsed with 10 mL of basal culture medium, and the cell suspension outside the strainer was collected.

[0089] The collected cell suspension was centrifuged at 400 g for 5 min at room temperature. The supernatant was discarded, and the cell pellet was retained. 13 mL of room temperature RBC lysis buffer (purchased from BioGems) was added to the pellet. The cell clumps were gently dispersed by pipetting. The reaction was carried out at room temperature for 1 min to complete the lysis of red blood cells. Then, 37 mL of basal culture medium was added and mixed thoroughly to terminate the lysis reaction. The mixture was centrifuged again at 400 g for 5 min at room temperature. The supernatant was discarded, and the cell pellet was retained.

[0090] Add 40 mL of pre-warmed basal culture medium to the pellet, and gently resuspend the cells using a pipette to complete the first cell wash. After washing, centrifuge at 400 g for 5 min at room temperature, discard the supernatant and retain the cell pellet, then add 20 mL of pre-warmed basal culture medium and gently resuspend the cells using a pipette. Filter the resuspended cell suspension again through a cell sieve to remove cell clumps, obtaining a single-cell suspension of spleen cells.

[0091] 1.4 B lymphocyte sorting:

[0092] B lymphocytes were sorted from the spleen cells obtained in Section 1.3 using the method described in Chinese Patent Document CN 110016462 A (publication date: July 16, 2019).

[0093] 1.5 B lymphocyte culture:

[0094] B lymphocytes obtained from section 1.4 were cultured using the method described in Chinese patent document CN 111518765 A (publication date: August 11, 2020).

[0095] 1.6 Cloning of the rabbit monoclonal antibody encoding gene

[0096] Positive clones were identified from the culture supernatant of B lymphocytes cultured in section 1.5 using an antigen-coated ELISA method, and wells secreting anti-mouse CD36 antibodies were screened. B lymphocytes from each positive well were collected, and total RNA was extracted using the Quick-RNA MicroPrep kit (ZYMO), which was then reverse transcribed into cDNA. Since each positive well originated from a single B cell clone, its VL and VH genes were naturally paired. Using the reverse-transcribed cDNA as a template, the light chain variable region (VL) and heavy chain variable region (VH) genes of each positive clone were amplified by PCR. Several clones were selected and sent to Kinkai Biotechnology Co., Ltd. for sequencing.

[0097] PCR amplification reaction system (total volume 25 μL): 4 μL cDNA template, 1 μL 10 μM forward primer, 1 μL 10 μM reverse primer, 12.5 μL Gloria Nova HS 2X Master Mix (Wuhan Aibotek Biotechnology Co., Ltd., catalog number RM20408), and 6.5 μL sterile deionized water. The nucleotide sequence of the forward primer (5'→3') for the light chain variable region is shown in SEQ ID NO:15, and the reverse primer (5'→3') is shown in SEQ ID NO:16; the forward primer (5'→3') for the heavy chain variable region is shown in SEQ ID NO:17, and the reverse primer (5'→3') is shown in SEQ ID NO:18.

[0098] The PCR amplification program was set as follows: 98℃ pre-denaturation for 30 s; followed by 40 cycles with the following parameters: 98℃ denaturation for 10 s, 64℃ annealing for 30 s, and 72℃ extension for 30 s; after the cycles, a final extension at 72℃ for 5 min was performed. After the reaction, the amplification products were stored at 4℃. A negative control without cDNA template was also included during the amplification process to exclude nonspecific amplification.

[0099] 1.7 Components of the Expression Carrier

[0100] The heavy chain and light chain expression vector maps used in this experiment are shown below. Figure 1 and Figure 2 The main elements of the vector are as follows: pBR322 origin and f1 origin are the initiation elements for the replication of the expression vector in E. coli; Ampicillin is the plasmid resistance selection gene; CMV immearly promoter is the eukaryotic expression promoter; and SV40 PAterminator is the transcription termination and tailing signal. Figure 1 The Heavy Chain Constant is the nucleotide sequence of the heavy chain constant region of the candidate antibody. Figure 2 The Light Chain Constant is the nucleotide sequence of the light chain constant region of the candidate antibody.

[0101] 1.8 Linearization of expression vector by enzyme digestion

[0102] The expression vector containing the A heavy chain constant region of rabbit monoclonal antibody was expressed using the restriction endonuclease NheI. Figure 1 Linearization was achieved by enzyme digestion, and the expression vector containing the constant region of the rabbit monoclonal antibody A light chain was linearized using the restriction endonuclease XbaI. Figure 2 The enzyme was used to linearize the product, and the linearized product was purified for later use.

[0103] 1.9 Construction and Identification of Recombinant Expression Vectors

[0104] The PCR amplification products of the heavy chain variable region gene and the light chain variable region gene from each positive clone obtained in Section 1.6 were purified separately, and the heavy chain variable region gene and the light chain variable region gene were cloned into the corresponding linearized expression vectors prepared in Section 1.8 via homologous recombination. After transformation of E. coli with the recombinant vectors, candidate clones were selected for sequencing verification. The recombinant expression vectors that were correctly sequenced were used for subsequent experiments.

[0105] 1.10 Expression and Screening of Rabbit Monoclonal Antibody A

[0106] Expression vectors containing both heavy and light chain genes, verified by sequencing, were co-transfected into 293F cells. After transfection and culture for 72–96 h, recombinant rabbit monoclonal antibodies were obtained from the culture supernatant. By comparing the binding activities of various candidate antibodies, rabbit monoclonal antibody A, which specifically recognizes mouse CD36, was selected.

[0107] 1.11 Purification and Preservation of Rabbit Monoclonal Antibody A

[0108] Recombinant rabbit monoclonal antibody A was purified from the culture supernatant after transfection using Protein A affinity gel resin. After the purity was verified by 12% SDS-PAGE gel electrophoresis, the antibody was aliquoted and stored at -20℃ for later use.

[0109] 1.12 Rabbit monoclonal antibody A sequencing

[0110] The purified rabbit monoclonal antibody A was sent to Kinkai Biotechnology Co., Ltd. for sequencing, and the following information about rabbit monoclonal antibody A was obtained:

[0111] The full-length amino acid sequence of the light chain is shown in SEQ ID NO:1;

[0112] The amino acid sequence of the light chain variable region is shown in SEQ ID NO:2;

[0113] The amino acid sequence of LCDR1, the complementarity-determining region of the light chain variable region, is shown in SEQ ID NO:3;

[0114] The amino acid sequence of the complementarity-determining region LCDR2 in the light chain variable region is shown in SEQ ID NO:4;

[0115] The amino acid sequence of LCDR3, the complementarity-determining region of the light chain variable region, is shown in SEQ ID NO:5;

[0116] The full-length amino acid sequence of the heavy chain is shown in SEQ ID NO:6;

[0117] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:7;

[0118] The amino acid sequence of HCDR1, the complementarity-determining region of the heavy chain variable region, is shown in SEQ ID NO:8;

[0119] The amino acid sequence of the complementarity-determining region HCDR2 in the heavy chain variable region is shown in SEQ ID NO:9;

[0120] The amino acid sequence of HCDR3, the complementarity-determining region of the heavy chain variable region, is shown in SEQ ID NO:10;

[0121] The full-length nucleotide sequence of the light chain is shown in SEQ ID NO:11;

[0122] The nucleotide sequence (5'→3') of the light chain variable region is shown in SEQ ID NO:12;

[0123] The full-length nucleotide sequence of the heavy chain (5'→3') is shown in SEQ ID NO:13;

[0124] The nucleotide sequence (5'→3') of the heavy chain variable region is shown in SEQ ID NO:14.

[0125] Example 2: Flow cytometry verification of rabbit monoclonal antibody A

[0126] The APC-labeled rabbit monoclonal antibody A used in this embodiment was prepared by coupling APC fluorescent dye to the unlabeled rabbit monoclonal antibody A obtained in Example 1: APC was coupled to the lysine amino group of the antibody using the NHS ester activation method, and the free dye was removed by gel filtration chromatography to obtain APC-labeled rabbit monoclonal antibody A, which was stored at 4°C in the dark for later use.

[0127] To verify that rabbit monoclonal antibody A can specifically recognize mouse CD36 on the surface of mouse cells, this example used C57BL / 6 mouse bone marrow-induced macrophages M0 as positive samples and detected them by flow cytometry using membrane staining. The experiment was set up with the following groups:

[0128] Rabbit monoclonal antibody group A: APC-labeled rabbit monoclonal antibody A + ABflo® 488-labeled rabbit anti-mouse F4 / 80 monoclonal antibody (commercially available product from Wuhan Aibotek Biotechnology Co., Ltd., catalog number: A27479) + C57BL / 6 mouse bone marrow-induced macrophages M0, after incubation, were detected by flow cytometry.

[0129] Isotype control group: APC Rabbit IgG isotype control (Wuhan Aibotek Biotechnology Co., Ltd., A24173) + ABflo® 488-labeled rabbit anti-mouse F4 / 80 monoclonal antibody (commercial product of Wuhan Aibotek Biotechnology Co., Ltd., catalog number: A27479) + C57BL / 6 mouse bone marrow-induced macrophages M0, after incubation, were detected by flow cytometry.

[0130] Commercially available antibody control group: Commercially available APC-labeled murine CD36 monoclonal antibody + ABflo® 488-labeled rabbit anti-mouse F4 / 80 monoclonal antibody (commercially available product from Wuhan Aibotek Biotechnology Co., Ltd., catalog number: A27479) + C57BL / 6 mouse bone marrow-induced macrophages M0, after incubation, were detected by flow cytometry.

[0131] The specific steps of the experiment are as follows:

[0132] 2.1 Experimental Preparation:

[0133] Turn on the ultraviolet lamp to disinfect the clean bench for 15-20 minutes, then turn on the ventilation equipment for 5 minutes to establish a sterile operating environment.

[0134] 2.2 Staining method:

[0135] (1) Collect positive samples (C57BL / 6 mouse bone marrow induced macrophages M0), count them, and detect cell viability at the same time. The cell viability should be maintained at around 95% and not lower than 90%.

[0136] (2) Resuspend the cells in 1×PBS solution and adjust the cell concentration to 3×10⁻⁶. 6 ~5×10 6 Cells / mL; aliquot the cell suspension into 96-well V-plates, 100 μL per well, and wash once with 1×PBS.

[0137] (3) Live / Dead (Zombie NIR) staining: The L / D staining working solution was diluted with 1×PBS at a ratio of 1:1500. 100 μL of the diluted staining working solution was added to each well of a 96-well V-plate according to the experimental design. The cells were then resuspended and mixed.

[0138] (4) Wrap the well plate with aluminum foil to protect it from light, and place it on a microplate shaker to gently mix and stain for 15 min.

[0139] (5) After centrifuging at 400 g for 5 min, discard the supernatant and wash twice with FACS buffer.

[0140] (6) Subsequently, F4 / 80 staining of the cell membrane surface was performed: ABflo® 488-labeled rabbit anti-mouse F4 / 80 monoclonal antibody (5 μL / Test) was used for surface staining and incubated at room temperature in the dark for 15-20 min; after incubation, the supernatant was discarded after centrifugation at 400 g for 3 min and washed once with FACS buffer.

[0141] (7) Resuspend the cells in FACS buffer and aliquot them into 96-well plates, 50 μL / well (cells per well < 10 cells). 6 Then add 50 μL / well of APC-labeled rabbit monoclonal antibody A (rabbit monoclonal antibody A group) or APC Rabbit IgG isotype control (isotype control group) diluted with FACS buffer and mix the cells.

[0142] (8) Wrap the perforated plate with aluminum foil to protect it from light, and place it on a microplate shaker to gently mix and incubate for 15-20 min.

[0143] (9) After centrifuging at 400 g for 5 min, discard the supernatant and wash twice with FACS buffer.

[0144] (10) Add 200 μL of FACS buffer to each well to resuspend the cells, store in the dark, and wait for flow cytometry analysis.

[0145] 2.3 Flow cytometry analysis:

[0146] Cells treated in section 2.2 were analyzed using flow cytometry. The procedure was strictly performed according to the Beckman CytoFLEX flow cytometer standard operating procedure (SOP-105-AND-CA-008). The results are as follows: Figure 3 , Figure 4 As shown.

[0147] Figure 3 The results indicate that when C57BL / 6 mouse bone marrow-induced macrophage M0 cells were used as the detection target, the proportion of CD36-positive cells detected by APC-labeled rabbit monoclonal antibody A (approximately 99.4%) was significantly higher than that detected by APC-labeled isotype antibody (approximately 0.47%). This suggests that the positive signal detected in this study is a mouse CD36-specific signal, and therefore the antibody specificity is considered to be qualified.

[0148] Figure 4 The results show that when C57BL / 6 mouse bone marrow-induced macrophage M0 cells were used as the test subject, the percentage of CD36-positive cells detected by the commercially available APC-labeled antibody was approximately 99.8%, indicating that the positive signal in this test was a mouse CD36-specific signal, and therefore the antibody specificity was considered to be qualified.

[0149] The above results indicate that the rabbit monoclonal antibody A prepared in this invention can specifically bind to mouse CD36 on the surface of mouse macrophages, which can meet the application requirements of flow cytometry detection of mouse CD36 positive cells.

[0150] The above description is merely a specific embodiment of the present invention, enabling those skilled in the art to understand or implement the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention. Therefore, the present invention is not to be limited to the embodiments shown herein, but is to be accorded the widest scope consistent with the principles and novel features claimed herein.

Claims

1. A rabbit monoclonal antibody against mouse CD36, characterized in that, It includes complementary determinants of the variable regions of light chains, LCDR1, LCDR2, and LCDR3, and complementary determinants of the variable regions of heavy chains, HCDR1, HCDR2, and HCDR3; wherein: The amino acid sequence of LCDR1 is shown in SEQ ID NO:3, the amino acid sequence of LCDR2 is shown in SEQ ID NO:4, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:

5. The amino acid sequence of HCDR1 is shown in SEQ ID NO:8, the amino acid sequence of HCDR2 is shown in SEQ ID NO:9, and the amino acid sequence of HCDR3 is shown in SEQ ID NO:

10.

2. The rabbit monoclonal antibody according to claim 1, characterized in that, The rabbit monoclonal antibody comprises a light chain variable region with an amino acid sequence as shown in SEQ ID NO:2, and a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:

7.

3. The rabbit monoclonal antibody according to claim 1, characterized in that, The rabbit monoclonal antibody is rabbit IgG, which has a light chain with an amino acid sequence as shown in SEQ ID NO:1 and a heavy chain with an amino acid sequence as shown in SEQ ID NO:

6.

4. The rabbit monoclonal antibody according to claim 1, characterized in that, The rabbit monoclonal antibody is a full-length antibody or its antigen-binding fragment; the antigen-binding fragment is selected from at least one of the Fab fragment, F(ab')2 fragment, Fv fragment, scFv fragment and (scFv)2 fragment.

5. A nucleic acid molecule, characterized in that, The nucleic acid molecule contains a nucleotide sequence encoding the rabbit monoclonal antibody of any one of claims 1 to 4.

6. A recombinant vector, characterized in that, Carrying the nucleic acid molecule as described in claim 5.

7. A host cell, characterized in that, It comprises the nucleic acid molecule of claim 5 or the recombinant vector of claim 6.

8. An antibody conjugate, characterized in that, It comprises a rabbit monoclonal antibody as described in any one of claims 1 to 4, and a detection marker linked to the rabbit monoclonal antibody.

9. A kit for detecting CD36 in mice, characterized in that, The kit contains: (1) Detection of an effective amount of the rabbit monoclonal antibody according to any one of claims 1 to 4; (2) The reagents for detection are selected from one or more of the following: buffer solution, labeled secondary antibody, blocking agent, washing solution and chromogenic substrate.

10. The use of the rabbit monoclonal antibody according to any one of claims 1 to 4 in the preparation of a product for detecting mouse CD36, wherein the detection is performed by flow cytometry.

Citation Information

Patent Citations

  • Method for efficiently separating single antigen-specific B lymphocyte from spleen cells

    CN110016462A

  • B lymphocyte in vitro culture system and applications thereof

    CN111518765A